Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Dr Reddys Laboratories (RDY) Other Accumulated Expenses (2025 - 2026)

Dr Reddys Laboratories has reported Other Accumulated Expenses over the past 2 years, most recently at $549.8 million for Q1 2026.

For Q1 2026, Other Accumulated Expenses rose 4.67% year-over-year to $549.8 million; the TTM value through Mar 2026 reached $549.8 million, up 4.67%, while the annual FY2026 figure was $549.8 million, 2.16% up from the prior year.
Other Accumulated Expenses for Q1 2026 was $549.8 million at Dr Reddys Laboratories, up from $525.3 million in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $549.8 million in Q1 2026 and troughed at $525.3 million in Q1 2025.